Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA 92093, United States of America; Department of Pathology and Medicine, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America.
Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, United States of America; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, United States of America.
Exp Neurol. 2023 May;363:114375. doi: 10.1016/j.expneurol.2023.114375. Epub 2023 Mar 11.
Microglia, the resident macrophage of the central nervous system, are increasingly recognized as contributing to diverse aspects of human development, health, and disease. In recent years, numerous studies in both mouse and human models have identified microglia as a "double edged sword" in the progression of neurotropic viral infections: protecting against viral replication and cell death in some contexts, while acting as viral reservoirs and promoting excess cellular stress and cytotoxicity in others. It is imperative to understand the diversity of human microglial responses in order to therapeutically modulate them; however, modeling human microglia has been historically challenging due to significant interspecies differences in innate immunity and rapid transformation upon in vitro culture. In this review, we discuss the contribution of microglia to the neuropathogenesis of key neurotropic viral infections: human immunodeficiency virus 1 (HIV-1), Zika virus (ZIKV), Japanese encephalitis virus (JEV), West Nile virus (WNV), Herpes simplex virus (HSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We pay special attention to recent work with human stem cell-derived microglia and propose strategies to leverage these powerful models to further uncover species- and disease-specific microglial responses and novel therapeutic interventions for neurotropic viral infections.
小胶质细胞是中枢神经系统的常驻巨噬细胞,它们在人类的发育、健康和疾病的多个方面发挥作用,这一点正日益得到人们的认识。近年来,在小鼠和人类模型中进行的大量研究表明,小胶质细胞在神经亲和性病毒感染的进展中是一把“双刃剑”:在某些情况下可以防止病毒复制和细胞死亡,而在其他情况下则充当病毒储存库,并促进过度的细胞应激和细胞毒性。为了进行治疗性调节,了解人类小胶质细胞反应的多样性至关重要;然而,由于先天免疫和体外培养后迅速转化方面存在显著的种间差异,因此对人类小胶质细胞进行建模在历史上一直具有挑战性。在这篇综述中,我们讨论了小胶质细胞对关键神经亲和性病毒感染的神经发病机制的贡献:人类免疫缺陷病毒 1(HIV-1)、寨卡病毒(ZIKV)、日本脑炎病毒(JEV)、西尼罗河病毒(WNV)、单纯疱疹病毒(HSV)和严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)。我们特别关注了最近使用人类干细胞衍生的小胶质细胞的研究,并提出了利用这些强大模型的策略,以进一步揭示种属特异性和疾病特异性的小胶质细胞反应,并为神经亲和性病毒感染提供新的治疗干预措施。